Resident since 2022

Medical technology, equipment and biopharma

Validity period
20 years
8 (495)280-10-02
The company will develop and produce biotechnological medicines based on monoclonal antibodies in a full cycle, starting from the production stage of the active pharmaceutical substance.

The expected volume of output is up to 120 kilograms of active biopharmaceutical substances and up to five million vials of finished product per year.

Biotechnological preparations will be created using DNA recombinant technology or controlled gene expression technology. The advantage of biotechnological drugs is their high specificity to the factors of the occurrence and development of the disease.

Наш сайт использует файлы cookie для хранения данных.
Продолжая использовать сайт, вы даёте согласие на работу с этими файлами.